Radionuclide based imaging of prostate cancer

Current Topics in Medicinal Chemistry

Volumn 10, Issue 16, 2010, Pages 1600-1616

  Mease, Ronnie C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Antibodies; Imaging; Peptides; PET; Prostate Cancer; Radionuclides; Small molecules; SPECT

Indexed keywords

1 AMINOCYCLOBUTANE 1 CARBOXYLIC ACID C 11; 1 AMINOCYCLOBUTANE 1 CARBOXYLIC ACID F 18; 1 HYDROXYETHYLIDIENE DIPHOSPHONATE TC 99M; 11BETA FLUORO 19 NOR 5ALPHA DIHYDROTESTOSTERONE F 18; 11BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; 17ALPHA (2 IODOVINYL 5ALPHA DIHYDROTESTOSTERONE) I 125; 17ALPHA (2 IODOVINYL 7ALPHA METHYL 19 NORTESTOSTERONE) I 125; ACETIC ACID C 11; AH 111585; AH 111585 F 18; ANDROGEN RECEPTOR; CAPROMAB PENDETIDE IN 111; CHOLINE C 11; CHOLINE F 18; ETIDRONIC ACID TC 99M; FLUORINE 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; FLUOROPROPIONIC ACID F 18; GALACTOARGINYLGLYCYLASPARTIC ACID F 18; HYDROXYMETHYLENE DIPHOSPHONATE TC 99M; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591 IN 111; MONOCLONAL ANTIBODY J591 LU 177; MONOCLONAL ANTIBODY J591 TC 99M; MONOCLONAL ANTIBODY J591 Y 90; N (3 FLUORO 4 NITRONAPHTHYL) 5 NORBORNENE ENDO 2,3 DICARBOXYLIC IMIDE F 18; OSTEOLITE; RADIOPHARMACEUTICAL AGENT; TECHNESCAN; TP 3939; TP 3939 CU 64; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALGORITHM; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; IMAGE QUALITY; IMAGE RECONSTRUCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VASCULARIZATION;

EID: 77958004737     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610793176774     Document Type: Article

References (237)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics. 2009. CA Cancer J. Clin., 2009, 59, 225-249.
2. Kundra, V.; Silverman, P. M.; Matin, S. F.; Choi, H. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. AJR. Am. J. Roentgenol., 2007, 189, 830-844.
3. Schroder, F. H.; Hugosson, J.; Roobol, M. J.; Tammela, T. L.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; Denis, L. J.; Recker, F.; Berenguer, A.; Maattanen, L.; Bangma, C. H.; Aus, G.; Villers, A.; Rebillard, X.; van der Kwast, T.; Blijenberg, B. G.; Moss, S. M.; de Koning, H. J.; Auvinen, A. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med., 2009, 360, 1320-1328.
4. Smith, D. S.; Humphrey, P. A.; Catalona, W. J. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer, 1997, 80, 1852-6.
5. Thompson, I. M.; Pauler, D. K.; Goodman, P. J.; Tangen, C. M.; Lucia, M. S.; Parnes, H. L.; Minasian, L. M.; Ford, L. G.; Lippman, S. M.; Crawford, E. D.; Crowley, J. J.; Coltman, C. A., Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med., 2004, 350, 2239-46.
6. Yatani, R.; Chigusa, I.; Akazaki, K.; Stemmermann, G. N.; Welsh, R. A.; Correa, P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer, 1982, 29, 611-616.
7. Draisma, G.; Boer, R.; Otto, S. J.; van der Cruijsen, I. W.; Damhuis, R. A.; Schroder, F. H.; de Koning, H. J. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J. Natl. Cancer Inst., 2003, 95, 868-78.
8. Kelloff, G. J.; Choyke, P.; Coffey, D. S. Challenges in clinical prostate cancer: role of imaging. AJR. Am. J. Roentgenol., 2009, 192, 1455-1470.
9. Zaheer, A.; Cho, S. Y.; Pomper, M. G. New agents and techniques for imaging prostate cancer. J. Nucl. Med., 2009, 50, 1387-1390.
10. Hricak, H.; Choyke, P. L.; Eberhardt, S. C.; Leibel, S. A.; Scardino, P. T. Imaging prostate cancer: a multidisciplinary perspective. Radiology, 2007, 243, 28-53.
11. Emonds, K. M.; Swinnen, J. V.; Mortelmans, L.; Mottaghy, F. M. Molecular imaging of prostate cancer. Methods, 2009, 48, 193-199.
12. Picchio, M.; Crivellaro, C.; Giovacchini, G.; Gianolli, L.; Messa, C. PET-CT for treatment planning in prostate cancer. Q. J. Nucl. Med. Mol. Imaging, 2009, 53, 245-268.
13. Schoder, H.; Larson, S. M. Positron emission tomography for prostate, bladder, and renal cancer. Semin. Nucl. Med., 2004, 34, 274-292.
14. Dotan, Z. A. Bone imaging in prostate cancer. Nat. Clin. Pract. Urol., 2008, 5, 434-444.
15. Pal, R. P.; Thiruudaian, T.; Khan, M. A. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J. Androl., 2008, 10, 890-895.
16. Beheshti, M.; Langsteger, W.; Fogelman, I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin. Nucl. Med., 2009, 39, 396-407.
17. Silberstein, E. B.; Francis, M. D.; Tofe, A. J.; Slough, C. L. Distribution of 99mTc-Sn diphosphonate and free 99mTc-pertechnetate in selected soft and hard tissues. J. Nucl. Med., 1975, 16, 58-61.
18. Francis, M. D.; Ferguson, D. L.; Tofe, A. J.; Bevan, J. A.; Michaels, S. E. Comparative evaluation of three diphosphonates: in vitro adsorption (C- 14 labeled) and in vivo osteogenic uptake (Tc- 99m complexed). J Nucl Med 1980, 21, 1185-1189.
19. Subramanian, G.; McAfee, J. G.; Bell, E. G.; Blair, R. J.; O'Mara, R. E.; Ralston, P. H. 99m Tc-labeled polyphosphate as a skeletal imaging agent. Radiology, 1972, 102, 701-704.
20. 99mTc skeletal imaging agents. cJ. Am. Chem. Soc., 1980, 102, 2476-2478.
21. Blau, M.; Ganatra, R.; Bender, M. A. 18 F-fluoride for bone imaging. Semin Nucl. Med., 1972, 2, 31-37.
22. Hawkins, R. A.; Choi, Y.; Huang, S. C.; Hoh, C. K.; Dahlbom, M.; Schiepers, C.; Satyamurthy, N.; Barrio, J. R.; Phelps, M. E. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J. Nucl. Med., 1992, 33, 633-642.
23. Schiepers, C.; Nuyts, J.; Bormans, G.; Dequeker, J.; Bouillon, R.; Mortelmans, L.; Verbruggen, A.; De Roo, M. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J. Nucl. Med., 1997, 38, 1970-1976.
24. Grant, F. D.; Fahey, F. H.; Packard, A. B.; Davis, R. T.; Alavi, A.; Treves, S. T. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J. Nucl. Med., 2008, 49, 68-78.
25. Cook, G. J.; Fogelman, I. The role of positron emission tomography in skeletal disease. Semin. Nucl. Med., 2001, 31, 50-61.
26. Hoegerle, S.; Juengling, F.; Otte, A.; Altehoefer, C.; Moser, E. A.; Nitzsche, E. U. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology, 1998, 209, 253-258.
27. Schirrmeister, H.; Glatting, G.; Hetzel, J.; Nussle, K.; Arslandemir, C.; Buck, A. K.; Dziuk, K.; Gabelmann, A.; Reske, S. N.; Hetzel, M. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J. Nucl. Med., 2001, 42, 1800-1804.
28. Schirrmeister, H.; Guhlmann, A.; Elsner, K.; Kotzerke, J.; Glatting, G.; Rentschler, M.; Neumaier, B.; Trager, H.; Nussle, K.; Reske, S. N. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J. Nucl. Med., 1999, 40, 1623-1629.
29. Schirrmeister, H.; Guhlmann, A.; Kotzerke, J.; Santjohanser, C.; Kuhn, T.; Kreienberg, R.; Messer, P.; Nussle, K.; Elsner, K.; Glatting, G.; Trager, H.; Neumaier, B.; Diederichs, C.; Reske, S. N. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J. Clin. Oncol., 1999, 17, 2381-2389.
30. Even-Sapir, E.; Metser, U.; Mishani, E.; Lievshitz, G.; Lerman, H.; Leibovitch, I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J. Nucl. Med., 2006, 47, 287-297.
31. Jadvar, H. Molecular imaging of prostate cancer with 18F- fluorodeoxyglucose PET. Nat. Rev. Urol., 2009, 6, 317-323.
32. Effert, P. J.; Bares, R.; Handt, S.; Wolff, J. M.; Bull, U.; Jakse, G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol., 1996, 155, 994-998.
33. Liu, I. J.; Zafar, M. B.; Lai, Y. H.; Segall, G. M.; Terris, M. K. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology, 2001, 57, 108-111.
34. Hofer, C.; Laubenbacher, C.; Block, T.; Breul, J.; Hartung, R.; Schwaiger, M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol., 1999, 36, 31-35.
35. Shreve, P. D.; Grossman, H. B.; Gross, M. D.; Wahl, R. L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F- 18]fluoro-D-glucose. Radiology, 1996, 199, 751-756.
36. Richter, J. A.; Rodriguez, M.; Rioja, J.; Penuelas, I.; Marti Climent, J.; Garrastachu, P.; Quincoces, G.; Zudaire, J.; Garcia-Velloso, M. J. Dual tracer (11)C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol. Imaging Biol., 2010, 12, 210-217.
37. Schoder, H.; Herrmann, K.; Gonen, M.; Hricak, H.; Eberhard, S.; Scardino, P.; Scher, H. I.; Larson, S. M. 2-[18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin. Cancer Res., 2005, 11, 4761-4769.
38. Jadvar, H.; Xiankui, L.; Shahinian, A.; Park, R.; Tohme, M.; Pinski, J.; Conti, P. S. Glucose metabolism of human prostate cancer mouse xenografts. Mol. Imaging, 2005, 4, 91-97.
39. Oyama, N.; Kim, J.; Jones, L. A.; Mercer, N. M.; Engelbach, J. A.; Sharp, T. L.; Welch, M. J. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl. Med. Biol., 2002, 29, 783-790.
40. Oyama, N.; Akino, H.; Suzuki, Y.; Kanamaru, H.; Ishida, H.; Tanase, K.; Sadato, N.; Yonekura, Y.; Okada, K. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl. Med. Commun., 2001, 22, 963-969.
41. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G.; Maddon, P. J.; Heston, W. D.; Olson, W. C. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. USA, 2003, 100, 12590-12595.
42. Chang, S. S.; Heston, W. D. The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol., 2002, 7, 7-12.
43. Troyer, J. K.; Beckett, M. L.; Wright, G. L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer, 1995, 62, 552-558.
44. Troyer, J. K.; Beckett, M. L.; Wright, G. L., Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 1997, 30, 232-242.
45. Haseman, M. K.; Rosenthal, S. A.; Polascik, T. J. Capromab Pendetide imaging of prostate cancer. Cancer Biother. Radiopharm., 2000, 15, 131-140.
46. Manyak, M. J. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert. Rev. Anticancer Ther., 2008, 8, 175-181.
47. Elgamal, A. A.; Troychak, M. J.; Murphy, G. P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate, 1998, 37, 261-269.
48. Jana, S.; Blaufox, M. D. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl. Med., 2006, 36, 51-72.
49. Nagda, S. N.; Mohideen, N.; Lo, S. S.; Khan, U.; Dillehay, G.; Wagner, R.; Campbell, S.; Flanigan, R. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67, 834-840.
50. DeWyngaert, J. K.; Noz, M. E.; Ellerin, B.; Kramer, E. L.; Maguire, G. Q., Jr.; Zeleznik, M. P. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. Int. J. Radiat. Oncol. Biol. Phys., 2004, 60, 654-662.
51. Schettino, C. J.; Kramer, E. L.; Noz, M. E.; Taneja, S.; Padmanabhan, P.; Lepor, H. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR. Am. J. Roentgenol., 2004, 183, 519-524.
52. Hasegawa, B. H.; Wong, K. H.; Iwata, K.; Barber, W. C.; Hwang, A. B.; Sakdinawat, A. E.; Ramaswamy, M.; Price, D. C.; Hawkins, R. A. Dual-modality imaging of cancer with SPECT/CT. Technol. Cancer Res. Treat, 2002, 1, 449-458.
53. Seo, Y.; Franc, B. L.; Hawkins, R. A.; Wong, K. H.; Hasegawa, B. H. Progress in SPECT/CT imaging of prostate cancer. Technol. Cancer Res. Treat., 2006, 5, 329-336.
54. Kimura, M.; Tsivian, M.; Mouraviev, V.; Mayes, J. M.; Price, M. M.; Bannister, M. C.; Madden, J. F.; Wong, T. Z.; Polascik, T. J. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Int. J. Urol., 2009, 16, 971-975.
55. Mouraviev, V.; Madden, J. F.; Broadwater, G.; Mayes, J. M.; Burchette, J. L.; Schneider, F.; Smith, J.; Tsivian, M.; Wong, T.; Polascik, T. J. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J. Urol., 2009, 182, 938-947.
56. Seo, Y.; Aparici, C. M.; Cooperberg, M. R.; Konety, B. R.; Hawkins, R. A. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J. Nucl. Med., 2010, 51, 31-36.
57. Elsasser-Beile, U.; Reischl, G.; Wiehr, S.; Buhler, P.; Wolf, P.; Alt, K.; Shively, J.; Judenhofer, M. S.; Machulla, H. J.; Pichler, B. J. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J. Nucl. Med., 2009, 50, 606-611.
58. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 1997, 57, 3629-3634.
59. Nanus, D. M.; Milowsky, M. I.; Kostakoglu, L.; Smith-Jones, P. M.; Vallabahajosula, S.; Goldsmith, S. J.; Bander, N. H. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol., 2003, 170, S84-S88; discussion S88-S89.
60. Smith-Jones, P. M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S. J.; Bander, N. H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med., 2003, 44, 610-7.
61. Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Sheehan, C. E.; Vallabhajosula, S.; Goldsmith, S. J.; Ross, J. S.; Bander, N. H. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol., 2007, 25, 540-547.
62. Vallabhajosula, S.; Kuji, I.; Hamacher, K. A.; Konishi, S.; Kostakoglu, L.; Kothari, P. A.; Milowski, M. I.; Nanus, D. M.; Bander, N. H.; Goldsmith, S. J. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J. Nucl. Med., 2005, 46, 634-641.
63. Nargund, V.; Al Hashmi, D.; Kumar, P.; Gordon, S.; Otitie, U.; Ellison, D.; Carroll, M.; Baithun, S.; Britton, K. E. Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU Int., 2005, 95, 1232-1236.
64. Bander, N. H.; Trabulsi, E. J.; Kostakoglu, L.; Yao, D.; Vallabhajosula, S.; Smith-Jones, P.; Joyce, M. A.; Milowsky, M.; Nanus, D. M.; Goldsmith, S. J. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol., 2003, 170, 1717-1721.
65. Bander, N. H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol., 2005, 23, 4591-4601.
66. Yoshimoto, M.; Waki, A.; Yonekura, Y.; Sadato, N.; Murata, T.; Omata, N.; Takahashi, N.; Welch, M. J.; Fujibayashi, Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol., 2001, 28, 117-122.
67. Kihlberg, T.; Valind, S.; Langstrom, B. Synthesis of [1-11C], [2- 11C], [1-11C](2H3) and [2-11C](2H3)acetate for in vivo studies of myocardium using PET. Nucl. Med. Biol., 1994, 21, 1067-1072.
68. Shreve, P.; Chiao, P. C.; Humes, H. D.; Schwaiger, M.; Gross, M. D. Carbon-11-acetate PET imaging in renal disease. J. Nucl. Med., 1995, 36, 1595-1601.
69. Shreve, P. D.; Gross, M. D. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J. Nucl. Med., 1997, 38, 1305-1310.
70. Oyama, N.; Akino, H.; Kanamaru, H.; Suzuki, Y.; Muramoto, S.; Yonekura, Y.; Sadato, N.; Yamamoto, K.; Okada, K. 11C-acetate PET imaging of prostate cancer. J. Nucl. Med., 2002, 43, 181-186.
71. Albrecht, S.; Buchegger, F.; Soloviev, D.; Zaidi, H.; Vees, H.; Khan, H. G.; Keller, A.; Bischof Delaloye, A.; Ratib, O.; Miralbell, R. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 185-196.
72. Morris, M. J.; Scher, H. I. (11)C-acetate PET imaging in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 181-184.
73. Kato, T.; Tsukamoto, E.; Kuge, Y.; Takei, T.; Shiga, T.; Shinohara, N.; Katoh, C.; Nakada, K.; Tamaki, N. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 1492-1495.
74. Wachter, S.; Tomek, S.; Kurtaran, A.; Wachter-Gerstner, N.; Djavan, B.; Becherer, A.; Mitterhauser, M.; Dobrozemsky, G.; Li, S.; Potter, R.; Dudczak, R.; Kletter, K. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J. Clin. Oncol., 2006, 24, 2513-2519.
75. Piert, M.; Park, H.; Khan, A.; Siddiqui, J.; Hussain, H.; Chenevert, T.; Wood, D.; Johnson, T.; Shah, R. B.; Meyer, C. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J. Nucl. Med., 2009, 50, 1585-1593.
76. Vees, H.; Buchegger, F.; Albrecht, S.; Khan, H.; Husarik, D.; Zaidi, H.; Soloviev, D.; Hany, T. F.; Miralbell, R. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate- specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int., 2007, 99, 1415-1420.
77. Guhlke, S., Coenen, H.H., Stocklin, G. Fluoroacylation agents based on small nca [F-18]fluorocarboxylic acids. Appl. Radiat. Isot., 1994, 45, 715-727.
78. Pillarsetty, N.; Punzalan, B.; Larson, S. M. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J. Nucl. Med., 2009, 50, 1709-1714.
79. Roivainen, A.; Forsback, S.; Gronroos, T.; Lehikoinen, P.; Kahkonen, M.; Sutinen, E.; Minn, H. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur. J. Nucl. Med., 2000, 27, 25-32.
80. Hara, T.; Kosaka, N.; Shinoura, N.; Kondo, T. PET imaging of brain tumor with [methyl-11C]choline. J. Nucl. Med., 1997, 38, 842-847.
81. Hara, T.; Kosaka, N.; Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med., 1998, 39, 990-995.
82. Sutinen, E.; Nurmi, M.; Roivainen, A.; Varpula, M.; Tolvanen, T.; Lehikoinen, P.; Minn, H. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 317-24.
83. de Jong, I. J.; Pruim, J.; Elsinga, P. H.; Vaalburg, W.; Mensink, H. J. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol., 2003, 44, 32-38; discussion 38-39.
84. Giovacchini, G.; Picchio, M.; Coradeschi, E.; Scattoni, V.; Bettinardi, V.; Cozzarini, C.; Freschi, M.; Fazio, F.; Messa, C. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and antiandrogenic therapy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1065-1073.
85. Reske, S. N. [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1740-1741.
86. Reske, S. N.; Blumstein, N. M.; Neumaier, B.; Gottfried, H. W.; Finsterbusch, F.; Kocot, D.; Moller, P.; Glatting, G.; Perner, S. Imaging prostate cancer with 11C-choline PET/CT. J. Nucl. Med. 2006, 47, 1249-1254.
87. Krause, B. J.; Souvatzoglou, M.; Tuncel, M.; Herrmann, K.; Buck, A. K.; Praus, C.; Schuster, T.; Geinitz, H.; Treiber, U.; Schwaiger, M. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 18-23.
88. Giovacchini, G.; Picchio, M.; Coradeschi, E.; Bettinardi, V.; Gianolli, L.; Scattoni, V.; Cozzarini, C.; Di Muzio, N.; Rigatti, P.; Fazio, F.; Messa, C. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 301-309.
89. Reske, S. N.; Blumstein, N. M.; Glatting, G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 9-17.
90. Rinnab, L.; Mottaghy, F. M.; Blumstein, N. M.; Reske, S. N.; Hautmann, R. E.; Hohl, K.; Moller, P.; Wiegel, T.; Kuefer, R.; Gschwend, J. E. Evaluation of [11C]-choline positronemission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int., 2007, 100, 786-793.
91. Scattoni, V.; Picchio, M.; Suardi, N.; Messa, C.; Freschi, M.; Roscigno, M.; Da Pozzo, L.; Bocciardi, A.; Rigatti, P.; Fazio, F. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur. Urol., 2007, 52, 423-429.
92. Scher, B.; Seitz, M. PET/CT imaging of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 5-8.
93. DeGrado, T. R.; Coleman, R. E.; Wang, S.; Baldwin, S. W.; Orr, M. D.; Robertson, C. N.; Polascik, T. J.; Price, D. T. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res., 2001, 61, 110-117.
94. Hara, T.; Kosaka, N.; Kishi, H. Development of (18)Ffluoroethylcholine for cancer imaging with PET: synthesis, bio-chemistry, and prostate cancer imaging. J. Nucl. Med., 2002, 43, 187-199.
95. Pascali, G.; D'Antonio, L.; Bovone, P.; Gerundini, P.; August, T. Optimization of automated large-scale production of [(18)F]fluoroethylcholine for PET prostate cancer imaging. Nucl. Med. Biol. 2009, 36, 569-574.
96. Piel, M.; Bauman, A.; Baum, R. P.; Hohnemann, S.; Klette, I.; Wortmann, R.; Rosch, F. Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imaging. Bioorg. Med. Chem., 2007, 15, 3171-3175.
97. Zuhayra, M.; Alfteimi, A.; Papp, L.; Lutzen, U.; Lutzen, A.; Von Forstner, C.; Meller, B.; Henze, E. Simplified fast and high yielding automated synthesis of [18F]fluoroethylcholine for prostate cancer imaging. Bioorg. Med. Chem., 2008, 16, 9121-9126.
98. Kryza, D.; Tadino, V.; Filannino, M. A.; Villeret, G.; Lemoucheux, L. Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl. Med. Biol., 2008, 35, 255-260.
99. Price, D. T.; Coleman, R. E.; Liao, R. P.; Robertson, C. N.; Polascik, T. J.; DeGrado, T. R. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J. Urol., 2002, 168, 273-280.
100. Beheshti, M.; Vali, R.; Waldenberger, P.; Fitz, F.; Nader, M.; Hammer, J.; Loidl, W.; Pirich, C.; Fogelman, I.; Langsteger, W. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol. Imaging Biol., 2009, 11, 446-454.
101. Kwee, S. A.; Wei, H.; Sesterhenn, I.; Yun, D.; Coel, M. N. Localization of primary prostate cancer with dual-phase 18F- fluorocholine PET. J. Nucl. Med., 2006, 47, 262-269.
102. Schillaci, O.; Calabria, F.; Tavolozza, M.; Ciccio, C.; Carlani, M.; Caracciolo, C. R.; Danieli, R.; Orlacchio, A.; 18F- choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl. Med. Commun., 2010, 31, 39-45.
103. Pelosi, E.; Arena, V.; Skanjeti, A.; Pirro, V.; Douroukas, A.; Pupi, A.; Mancini, M. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol. Med., 2008, 113, 895-904.
104. Cimitan, M.; Bortolus, R.; Morassut, S.; Canzonieri, V.; Garbeglio, A.; Baresic, T.; Borsatti, E.; Drigo, A.; Trovo, M. G. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 1387-1398.
105. Beheshti, M.; Vali, R.; Waldenberger, P.; Fitz, F.; Nader, M.; Loidl, W.; Broinger, G.; Stoiber, F.; Foglman, I.; Langsteger, W. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1766-1774.
106. Leyton, J.; Smith, G.; Zhao, Y.; Perumal, M.; Nguyen, Q. D.; Robins, E.; Arstad, E.; Aboagye, E. O. [18F]fluoromethyl-[1,2-2H4]- choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. Cancer Res., 2009, 69, 7721-7728.
107. Connors, T. A.; Elson, L. A.; Haddow, A.; Ross, W. C. The pharmacology and tumour growth inhibitory activity of 1- aminocyclopentane-1-carboxylic acid and related compounds. Biochem. Pharmacol., 1960, 5, 108-129.
108. Hayes, R. L.; Washburn, L. C.; Wieland, B. W.; Sun, T. T.; Turtle, R. R.; Butler, T. A. Carboxyl-labeled 11C-1-aminocyclopentane-carboxylic acid, a potential agent for cancer detection. J. Nucl. Med. 1976, 17, 748-751.
109. Washburn, L. C.; Sun, T. T.; Byrd, B.; Hayes, R. L.; Butler, T. A. 1-aminocyclobutane[11C]carboxylic acid, a potential tumorseeking agent. J. Nucl. Med., 1979, 20, 1055-1061.
110. Hubner, K. F.; Andrews, G. A.; Washburn, L.; Wieland, B. W.; Gibbs, W. D.; Hayes, R. L.; Butler, T. A.; Winebrenner, J. D. Tumor location with 1-aminocyclopentane [11C] carboxylic acid: preliminary clinical trials with single-photon detection. J. Nucl. Med., 1977, 18, 1215-1221.
111. Shoup, T. M.; Olson, J.; Hoffman, J. M.; Votaw, J.; Eshima, D.; Eshima, L.; Camp, V. M.; Stabin, M.; Votaw, D.; Goodman, M. M. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1- carboxylic acid to image brain tumors. J. Nucl. Med., 1999, 40, 331-338.
112. Shoup TM, G. M. Synthesis of [F-18]-1-amino-3-fluorocyclo- butane-1-carboxylic acid (FACBC): A PET tracer for tumor delineation. J. Labelled Compd. Radiopharm., 1999, 42, 215-225.
113. McConathy, J.; Voll, R. J.; Yu, W.; Crowe, R. J.; Goodman, M. M. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl. Radiat. Isot., 2003, 58, 657-666.
114. Oka, S.; Hattori, R.; Kurosaki, F.; Toyama, M.; Williams, L. A.; Yu, W.; Votaw, J. R.; Yoshida, Y.; Goodman, M. M.; Ito, O. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J. Nucl. Med., 2007, 48, 46-55.
115. Schuster, D. M.; Votaw, J. R.; Nieh, P. T.; Yu, W.; Nye, J. A.; Master, V.; Bowman, F. D.; Issa, M. M.; Goodman, M. M. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclo- butane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med., 2007, 48, 56-63.
116. Janoff, D. M.; Peterson, C.; Mongoue-Tchokote, S.; Peters, L.; Beer, T. M.; Wersinger, E. M.; Mori, M.; Garzotto, M. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int., 2005, 96, 503-507.
117. Jereczek-Fossa, B. A.; Curigliano, G.; Orecchia, R. Systemic therapies for non-metastatic prostate cancer: review of the literature. Onkologie, 2009, 32, 359-363.
118. Hoyte, R. M.; Rosner, W.; Hochberg, R. B. Synthesis of 16 alpha- [125I] iodo-5 alpha dihydrotestosterone and evaluation of its affinity for the androgen receptor. J. Steroid Biochem., 1982, 16, 621-628.
119. Tarle, M.; Padovan, R.; Spaventi, S. The uptake of radioiodinated 5 alpha-dihydrotestosterone by the prostate of intact and castrated rats. Eur. J. Nucl. Med., 1981, 6, 79-83.
120. Eakins, M. N.; Waters, S. L. The synthesis of 77Br-labelled 5 alpha-dihydrotestosterone and a comparison of its distribution in rats with 77Br-bromide. Int. J. Appl. Radiat. Isot., 1979, 30, 701-703.
121. Ghanadian, R.; Waters, S. L.; Chisholm, G. D. Investigations into the use of 77Br labelled 5alpha-dihydrotestosterone for scanning the prostate. Eur. J. Nucl. Med., 1977, 2, 155-157.
122. Liu, A.; Carlson, K. E.; Katzenellenbogen, J. A. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J. Med. Chem., 1992, 35, 2113-2129.
123. Liu, A. J.; Katzenellenbogen, J. A.; VanBrocklin, H. F.; Mathias, C. J.; Welch, M. J. 20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J. Nucl. Med., 1991, 32, 81-88.
124. Liu, A.; Dence, C. S.; Welch, M. J.; Katzenellenbogen, J. A. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J. Nucl. Med., 1992, 33, 724-734.
125. Garg, P. K.; Labaree, D. C.; Hoyte, R. M.; Hochberg, R. B. [7alpha-18F]fluoro-17alpha-methyl-5alpha-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl. Med. Biol., 2001, 28, 85-90.
126. Choe, Y. S.; Lidstrom, P. J.; Chi, D. Y.; Bonasera, T. A.; Welch, M. J.; Katzenellenbogen, J. A. Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alphadihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. J. Med. Chem., 1995, 38, 816-825.
127. Hoyte, R. M.; MacLusky, N. J.; Hochberg, R. B. The synthesis and testing of E-17 alpha-(2-iodovinyl)-5 alpha-dihydrotestosterone and Z-17 alpha-(2-iodovinyl)-5 alpha-dihydrotestosterone as gamma-emitting ligands for the androgen receptor. J. Steroid Bio chem., 1990, 36, 125-132.
128. Hoyte, R. M.; Brown, T. J.; MacLusky, N. J.; Hochberg, R. B. 7 alpha-Methyl-17 alpha-(E-2'-[125I]iodovinyl)-19-nortestosterone: a new radioligand for the detection of androgen receptor. Steroids, 1993, 58, 13-23.
129. Hoyte, R. M.; Borderon, K.; Bryson, K.; Allen, R.; Hochberg, R. B.; Brown, T. J. Synthesis and evaluation of 7 alpha-iodo-5 alpha- dihydrotestosterone as a potential radioligand for androgen receptor. J. Med. Chem., 1994, 37, 1224-1230.
130. Labaree, D. C.; Brown, T. J.; Hoyte, R. M.; Hochberg, R. B. 7 alpha-iodine-125-iodo-5 alpha-dihydrotestosterone: a radiolabeled ligand for the androgen receptor. J. Nucl. Med., 1997, 38, 402-109.
131. Ali, H.; Rousseau, J.; Ahmed, N.; Guertin, V.; Hochberg, R. B.; van Lier, J. E. Synthesis of the 7alpha-cyano-(17alpha,20E/Z)- [125I]iodovinyl-19-nortestosterones: potential radioligands for androgen and progesterone receptors. Steroids, 2003, 68, 1163-1171.
132. Bonasera, T. A.; O'Neil, J. P.; Xu, M.; Dobkin, J. A.; Cutler, P. D.; Lich, L. L.; Choe, Y. S.; Katzenellenbogen, J. A.; Welch, M. J. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J. Nucl. Med., 1996, 37, 1009-1015.
133. Larson, S. M.; Morris, M.; Gunther, I.; Beattie, B.; Humm, J. L.; Akhurst, T. A.; Finn, R. D.; Erdi, Y.; Pentlow, K.; Dyke, J.; Squire, O.; Bornmann, W.; McCarthy, T.; Welch, M.; Scher, H. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med., 2004, 45, 366-373.
134. Parent, E. E.; Carlson, K. E.; Katzenellenbogen, J. A. Synthesis of 7alpha-(fluoromethyl)dihydrotestosterone and 7alpha-(fluoromethyl)nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emission tomography. J. Org. Chem., 2007, 72, 5546-5554.
135. Parent, E. E.; Dence, C. S.; Sharp, T. L.; Welch, M. J.; Katzenellenbogen, J. A. 7alpha-18F-fluoromethyl-dihydrotestosterone and 7alpha-18F-fluoromethyl-nortestosterone: ligands to determine the role of sex hormone-binding globulin for steroidal radiopharmaceuticals. J. Nucl. Med., 2008, 49, 987-994.
136. Dehdashti, F.; Picus, J.; Michalski, J. M.; Dence, C. S.; Siegel, B. A.; Katzenellenbogen, J. A.; Welch, M. J. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 344-350.
137. Beattie, B. J.; Smith-Jones, P. M.; Jhanwar, Y. S.; Schoder, H.; Schmidtlein, C. R.; Morris, M. J.; Zanzonico, P.; Squire, O.; Meirelles, G. S.; Finn, R.; Namavari, M.; Cai, S.; Scher, H. I.; Larson, S. M.; Humm, J. L. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med., 2010, 51, 183-192.
138. Dalton, J. T.; Mukherjee, A.; Zhu, Z.; Kirkovsky, L.; Miller, D. D. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun., 1998, 244, 1-4.
139. Parent, E. E.; Dence, C. S.; Jenks, C.; Sharp, T. L.; Welch, M. J.; Katzenellenbogen, J. A. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br] bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging. J. Med. Chem., 2007, 50, 1028-1040.
140. Jacobson, O.; Bechor, Y.; Icar, A.; Novak, N.; Birman, A.; Marom, H.; Fadeeva, L.; Golan, E.; Leibovitch, I.; Gutman, M.; Even-Sapir, E.; Chisin, R.; Gozin, M.; Mishani, E. Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. Bioorg. Med. Chem., 2005, 13, 6195-6205.
141. Parent, E. E.; Jenks, C.; Sharp, T.; Welch, M. J.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromohydroxyflutamide. Nucl. Med. Biol., 2006, 33, 705-713.
142. Parent, E. E.; Dence, C. S.; Sharp, T. L.; Welch, M. J.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a fluorine18-labeled nonsteroidal androgen receptor antagonist, N-(3- [18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicar- boxylic imide. Nucl. Med. Biol., 2006, 33, 615-624.
143. Clezardin, P. Recent insights into the role of integrins in cancer metastasis. Cell Mol. Life Sci., 1998, 54, 541-548.
144. Eliceiri, B. P.; Cheresh, D. A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest, 1999, 103, 1227-1230.
145. D'Andrea, L. D.; Del Gatto, A.; Pedone, C.; Benedetti, E. Peptidebased molecules in angiogenesis. Chem. Biol. Drug Des., 2006, 67, 115-126.
146. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S.L. Jonczyk, A., Kessler, H. Structural and functional aspects of RGD- containing cyclic pentapeptides as highly potent and selective integrin v 3 antagonists. J. Am. Chem. Soc., 1996, 118, 7461-7472.
147. Haubner, R.; Wester, H. J.; Reuning, U.; Senekowitsch-Schmidtke, R.; Diefenbach, B.; Kessler, H.; Stocklin, G.; Schwaiger, M. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med., 1999, 40, 1061-1071.
148. Cai, W.; Niu, G.; Chen, X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des., 2008, 14, 2943-2973.
149. Dijkgraaf, I.; Beer, A. J.; Wester, H. J. Application of RGD- containing peptides as imaging probes for alphavbeta3 expression. Front Biosci., 2009, 14, 887-99.
150. Haubner, R.; Wester, H. J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des., 2004, 10, 1439-1455.
151. Haubner, R.; Kuhnast, B.; Mang, C.; Weber, W. A.; Kessler, H.; Wester, H. J.; Schwaiger, M. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug. Chem., 2004, 15, 61-69.
152. Haubner, R.; Wester, H. J.; Weber, W. A.; Mang, C.; Ziegler, S. I.; Goodman, S. L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwaiger, M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res., 2001, 61, 1781-1785.
153. Beer, A. J.; Grosu, A. L.; Carlsen, J.; Kolk, A.; Sarbia, M.; Stangier, I.; Watzlowik, P.; Wester, H. J.; Haubner, R.; Schwaiger, M. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res., 2007, 13, 6610-6.
154. Beer, A. J.; Niemeyer, M.; Carlsen, J.; Sarbia, M.; Nahrig, J.; Watzlowik, P.; Wester, H. J.; Harbeck, N.; Schwaiger, M. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J. Nucl. Med., 2008, 49, 255-259.
155. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K. F.; Goebel, M.; Hein, R.; Wester, H. J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med., 2005, 2, e70.
156. Rokhlin, O. W.; Cohen, M. B. Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate, 1995, 26, 205-12.
157. van Hagen, P. M.; Breeman, W. A.; Bernard, H. F.; Schaar, M.; Mooij, C. M.; Srinivasan, A.; Schmidt, M. A.; Krenning, E. P.; de Jong, M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer, 2000, 90, 186-198.
158. Glaser, M.; Morrison, M.; Solbakken, M.; Arukwe, J.; Karlsen, H.; Wiggen, U.; Champion, S.; Kindberg, G. M.; Cuthbertson, A. Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups. Bioconjug. Chem., 2008, 19, 951-957.
159. Indrevoll, B.; Kindberg, G. M.; Solbakken, M.; Bjurgert, E.; Johansen, J. H.; Karlsen, H.; Mendizabal, M.; Cuthbertson, A. NC- 100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg. Med. Chem. Lett., 2006, 16, 6190-6193.
160. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P. S.; Hui, A. M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E. O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med., 2008, 49, 879-886.
161. Li, Z. B.; Wu, Z.; Chen, K.; Ryu, E. K.; Chen, X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med., 2008, 49, 453-461.
162. Liu, Z.; Li, Z. B.; Cao, Q.; Liu, S.; Wang, F.; Chen, X. Small- animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J. Nucl. Med., 2009, 50, 1168-1177.
163. Mitra, A.; Mulholland, J.; Nan, A.; McNeill, E.; Ghandehari, H.; Line, B. R. Targeting tumor angiogenic vasculature using polymer- RGD conjugates. J. Control Release, 2005, 102, 191-201.
164. Reubi, J. C.; Laderach, U.; Waser, B.; Gebbers, J. O.; Robberecht, P.; Laissue, J. A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res., 2000, 60, 3105-3112.
165. Zhang, K.; Aruva, M. R.; Shanthly, N.; Cardi, C. A.; Rattan, S.; Patel, C.; Kim, C.; McCue, P. A.; Wickstrom, E.; Thakur, M. L. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J. Nucl. Med., 2008, 49, 112-121.
166. Boswell, C. A.; Sun, X.; Niu, W.; Weisman, G. R.; Wong, E. H.; Rheingold, A. L.; Anderson, C. J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacro-cyclic complexes. J. Med. Chem., 2004, 47, 1465-1474.
167. Wong, E. H., Weisman, G.R., Hill, D.C., Reed, D.P., Rogers, M.E., Condon, J.S., Fagan, M.A., Calabrese, J.C., Lam, K-C., Guzei, I.A., Rheingold, A.L. Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes. J. Am. Chem. Soc., 2000, 122(43), 10561-10572
168. Boswell, C. A.; Regino, C. A.; Baidoo, K. E.; Wong, K. J.; Bumb, A.; Xu, H.; Milenic, D. E.; Kelley, J. A.; Lai, C. C.; Brechbiel, M. W. Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling. Bioconjug. Chem., 2008, 19, 1476-1484.
169. Liu, W.; Hao, G.; Long, M. A.; Anthony, T.; Hsieh, J. T.; Sun, X. Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angew. Chem. Int. Ed. Engl., 2009, 48, 7346-7349.
170. Peng, F.; Lu, X.; Janisse, J.; Muzik, O.; Shields, A. F. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J. Nucl. Med., 2006, 47, 1649-1652.
171. Barondes, S. H.; Cooper, D. N.; Gitt, M. A.; Leffler, H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem., 1994, 269, 20807-20810.
172. Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; Iacobelli, S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res., 2000, 6, 1389-1393.
173. Ahmed, H.; Banerjee, P. P.; Vasta, G. R. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem. Biophys. Res. Commun., 2007, 358, 241-246.
174. Pacis, R. A.; Pilat, M. J.; Pienta, K. J.; Wojno, K.; Raz, A.; Hogan, V.; Cooper, C. R. Decreased galectin-3 expression in prostate cancer. Prostate, 2000, 44, 118-123.
175. Deutscher, S. L.; Figueroa, S. D.; Kumar, S. R. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl. Med. Biol., 2009, 36, 137-146.
176. Markwalder, R.; Reubi, J. C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res., 1999, 59, 1152-1159.
177. de Visser, M.; van Weerden, W. M.; de Ridder, C. M.; Reneman, S.; Melis, M.; Krenning, E. P.; de Jong, M. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J. Nucl. Med., 2007, 48, 88-93.
178. Maina, T.; Nock, B.; Mather, S. Targeting prostate cancer with radiolabelled bombesins. Cancer Imaging, 2006, 6, 153-157.
179. Schroeder, R. P.; van Weerden, W. M.; Bangma, C.; Krenning, E. P.; de Jong, M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods, 2009, 48, 200-4.
180. Varvarigou, A.; Bouziotis, P.; Zikos, C.; Scopinaro, F.; De Vincentis, G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother. Radiopharm., 2004, 19, 219-229.
181. Baidoo, K. E.; Lin, K. S.; Zhan, Y.; Finley, P.; Scheffel, U.; Wagner, H. N., Jr. Design, synthesis, and initial evaluation of high- affinity technetium bombesin analogues. Bioconjug. Chem., 1998, 9, 218-225.
182. Lin, K. S.; Luu, A.; Baidoo, K. E.; Hashemzadeh-Gargari, H.; Chen, M. K.; Brenneman, K.; Pili, R.; Pomper, M.; Carducci, M. A.; Wagner, H. N., Jr. A new high affinity technetium-99m- bombesin analogue with low abdominal accumulation. Bioconjug. Chem., 2005, 16, 43-50.
183. Lin, K. S.; Luu, A.; Baidoo, K. E.; Hashemzadeh-Gargari, H.; Chen, M. K.; Pili, R.; Pomper, M.; Carducci, M.; Wagner, H. N., Jr. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjug. Chem., 2004, 15, 1416-1423.
184. Okarvi, S. M.; al-Jammaz, I. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res., 2003, 23, 2745-2750.
185. Smith, C. J.; Gali, H.; Sieckman, G. L.; Higginbotham, C.; Volkert, W. A.; Hoffman, T. J. Radiochemical investigations of (99m)Tc- N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug. Chem., 2003, 14, 93-102.
186. Blok, D.; Feitsma, H. I.; Kooy, Y. M.; Welling, M. M.; Ossendorp, F.; Vermeij, P.; Drijfhout, J. W. New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides. Nucl. Med. Biol., 2004, 31, 815-820.
187. Fragogeorgi, E. A.; Zikos, C.; Gourni, E.; Bouziotis, P.; Paravatou-Petsotas, M.; Loudos, G.; Mitsokapas, N.; Xanthopoulos, S.; Mavri-Vavayanni, M.; Livaniou, E.; Varvarigou, A. D.; Archimandritis, S. C. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X- Bombesin[2-14] Derivatives. Bioconjug. Chem., 2009, 20, 856-820.
188. Gourni, E.; Bouziotis, P.; Benaki, D.; Loudos, G.; Xanthopoulos, S.; Paravatou-Petsotas, M.; Mavri-Vavagianni, M.; Pelecanou, M.; Archimandritis, S. C.; Varvarigou, A. D. Structural assessment and biological evaluation of two N3S bombesin derivatives. J. Med. Chem., 2009, 52, 4234-4246.
189. Gourni, E.; Paravatou, M.; Bouziotis, P.; Zikos, C.; Fani, M.; Xanthopoulos, S.; Archimandritis, S. C.; Livaniou, E.; Varvarigou, A. D. Evaluation of a series of new 99mTc-labeled bombesin-like peptides for early cancer detection. Anticancer Res., 2006, 26, 435-438.
190. Nock, B.; Nikolopoulou, A.; Chiotellis, E.; Loudos, G.; Maintas, D.; Reubi, J. C.; Maina, T. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 247-258.
191. Nock, B. A.; Nikolopoulou, A.; Galanis, A.; Cordopatis, P.; Waser, B.; Reubi, J. C.; Maina, T. Potent bombesin-like peptides for GRP- receptor targeting of tumors with 99mTc: a preclinical study. J. Med. Chem., 2005, 48, 100-110.
192. Smith, C. J.; Sieckman, G. L.; Owen, N. K.; Hayes, D. L.; Mazuru, D. G.; Kannan, R.; Volkert, W. A.; Hoffman, T. J. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His- Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3- diaminopropionic acid and X = H2O or P(CH2OH)3. Cancer Res., 2003, 63, 4082-4088.
193. Smith, C. J.; Sieckman, G. L.; Owen, N. K.; Hayes, D. L.; Mazuru, D. G.; Volkert, W. A.; Hoffman, T. J. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7- 14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res., 2003, 23, 63-70.
194. Breeman, W. A.; de Jong, M.; Erion, J. L.; Bugaj, J. E.; Srinivasan, A.; Bernard, B. F.; Kwekkeboom, D. J.; Visser, T. J.; Krenning, E. P. Preclinical comparison of (111)In-labeled DTPA- or DOTA- bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med., 2002, 43, 1650-1656.
195. de Visser, M.; Bernard, H. F.; Erion, J. L.; Schmidt, M. A.; Srinivasan, A.; Waser, B.; Reubi, J. C.; Krenning, E. P.; de Jong, M. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1228-1238.
196. Hoffman, T. J.; Gali, H.; Smith, C. J.; Sieckman, G. L.; Hayes, D. L.; Owen, N. K.; Volkert, W. A. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J. Nucl. Med., 2003, 44, 823-831.
197. Zhang, H.; Chen, J.; Waldherr, C.; Hinni, K.; Waser, B.; Reubi, J. C.; Maecke, H. R. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium- 111, lutetium-177, and yttrium-90 for targeting bombesin receptor expressing tumors. Cancer Res., 2004, 64, 6707-6715.
198. Zhang, X.; Cai, W.; Cao, F.; Schreibmann, E.; Wu, Y.; Wu, J. C.; Xing, L.; Chen, X. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J. Nucl. Med., 2006, 47, 492-501.
199. Chen, X.; Park, R.; Hou, Y.; Tohme, M.; Shahinian, A. H.; Bading, J. R.; Conti, P. S. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med., 2004, 45, 1390-1397.
200. Rogers, B. E.; Bigott, H. M.; McCarthy, D. W.; Della Manna, D.; Kim, J.; Sharp, T. L.; Welch, M. J. MicroPET imaging of a gastrinreleasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug. Chem., 2003, 14, 756-763.
201. Rogers, B. E.; Manna, D. D.; Safavy, A. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother. Radiopharm., 2004, 19, 25-34.
202. Yang, Y. S.; Zhang, X.; Xiong, Z.; Chen, X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol., 2006, 33, 371-80.
203. Maecke, H. R.; Hofmann, M.; Haberkorn, U. (68)Ga-labeled peptides in tumor imaging. J. Nucl. Med., 2005, 46 (Suppl 1), 172S-178S.
204. Zhang, H.; Schuhmacher, J.; Waser, B.; Wild, D.; Eisenhut, M.; Reubi, J. C.; Maecke, H. R. DOcTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radi- onuclide treatment of bombesin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1198-1208.
205. Varvarigou, A. D.; Scopinaro, F.; Leondiadis, L.; Corleto, V.; Schillaci, O.; De Vincentis, G.; Sourlingas, T. G.; Sekeri-Pataryas, K. E.; Evangelatos, G. P.; Leonti, A.; Xanthopoulos, S.; Delle Fave, G.; Archimandritis, S. C. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin- like peptide. Cancer Biother. Radiopharm., 2002, 17, 317-326.
206. De Vincentis, G.; Remediani, S.; Varvarigou, A. D.; Di Santo, G.; Iori, F.; Laurenti, C.; Scopinaro, F. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother. Radio- pharm., 2004, 19, 81-84.
207. Scopinaro, F.; De Vincentis, G.; Varvarigou, A. D.; Laurenti, C.; Iori, F.; Remediani, S.; Chiarini, S.; Stella, S. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1378-1382.
208. Van de Wiele, C.; Dumont, F.; Vanden Broecke, R.; Oosterlinck, W.; Cocquyt, V.; Serreyn, R.; Peers, S.; Thornback, J.; Slegers, G.; Dierckx, R. A. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med., 2000, 27, 1694-1699.
209. Barinka, C.; Byun, Y.; Dusich, C. L.; Banerjee, S. R.; Chen, Y.; Castanares, M.; Kozikowski, A. P.; Mease, R. C.; Pomper, M. G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J. Med. Chem., 2008, 51, 7737-7743.
210. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J. Med. Chem., 2007, 50, 3267-373.
211. Barinka, C.; Starkova, J.; Konvalinka, J.; Lubkowski, J. A high- resolution structure of ligand-free human glutamate carboxypepti- dase II. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2007, 63, 150-153.
212. Supuran, C., Winum, J-Y. Drug Design of Zinc-Enzyme inhibitors. Chapter 36 Recent Deveopment of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII). John Wiley & Sons Hoboken, New Jersey, 2009.
213. Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov., 2005, 4, 1015-1026.
214. Foss, C. A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R. T.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G. Radiolabeled small-molecule ligands for prostate specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res., 2005, 11, 4022-4028.
215. Dusich, C. L., Chen, Y., Pullambhatla, M., Nimmagadda, S., Foss, C.A., Fox, J.J., Castanares, M., Mease, R.C., Pomper, M.G. Synthesis and in-vivo evaluation of 2-{-[1-carboxy-2-(4-[125I]iodo- benzylsulfanyl)-ethyl]-ureido}-pentanedioic acid) [125I]DCFBC). J. Labelled Compd. Radiopharm., 2009, 52, S18 (abstract).
216. Mease, R. C.; Dusich, C. L.; Foss, C. A.; Ravert, H. T.; Dannals, R. F.; Seidel, J.; Prideaux, A.; Fox, J. J.; Sgouros, G.; Kozikowski, A. P.; Pomper, M. G. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4- [18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin. Cancer Res., 2008, 14, 3036-3043.
217. Chen, Y.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J. J.; Castanares, M.; Lupold, S. E.; Babich, J. W.; Mease, R. C.; Pomper, M. G. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J. Med. Chem., 2008, 51, 7933-7943.
218. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate- specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res., 2009, 69, 6932-6940.
219. Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Zimmerman, C. N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J. W. A series of halogenated heterodi- meric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem., 2009, 52, 347-357.
220. Lapi, S. E.; Wahnishe, H.; Pham, D.; Wu, L. Y.; Nedrow-Byers, J. R.; Liu, T.; Vejdani, K.; VanBrocklin, H. F.; Berkman, C. E.; Jones, E. F. Assessment of an 18F-labeled phosphoramidate pepti domimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J. Nucl. Med., 2009, 50, 2042-2048.
221. Banerjee, S. R., Pullambhatla, M., Byun, Y., Green, G., Fox, J.J., Horti, A.G., Mease, R., Pomper, M.G. Ga-68- and In-111-labeled small molecule inhibitors of PSMA for prostate cancer imaging. J. Labelled Compd. Radiopharm., 2009, 52, S19 (abstract).
222. Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of technetium-99m- and rhenium- labeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem., 2008, 51, 4504-4517.
223. Kularatne, S. A.; Wang, K.; Santhapuram, H. K.; Low, P. S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm., 2009, 6, 780-789.
224. Kularatne, S. A.; Zhou, Z.; Yang, J.; Post, C. B.; Low, P. S. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol. Pharm., 2009, 6, 790-800.
225. Barrett, J., LaFrance, N., Coleman, R.E., Goldsmith, S., Stubbs, J., Petry, N., Vallabhajosula, S., Maresca, K., Femia, F., Babich, J. Targeting metastatic prostate cancer [PCa] in patients with 123I- MIP1072 & 123I-MIP1095. (Abstract). J. Nucl. Med., 2009, 50 (Suppl 2), 522.
226. Chandran, S. S.; Banerjee, S. R.; Mease, R. C.; Pomper, M. G.; Denmeade, S. R. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther., 2008, 7, 974-982.
227. Murelli, R. P.; Zhang, A. X.; Michel, J.; Jorgensen, W. L.; Spiegel, D. A. Chemical control over immune recognition: a class of anti-body-recruiting small molecules that target prostate cancer. J. Am. Chem. Soc., 2009, 131, 17090-17092.
228. Cerchia, L.; Giangrande, P. H.; McNamara, J. O.; de Franciscis, V. Cell-specific aptamers for targeted therapies. Methods Mol. Biol., 2009, 535, 59-78.
229. Hicke, B. J.; Stephens, A. W.; Gould, T.; Chang, Y. F.; Lynott, C. K.; Heil, J.; Borkowski, S.; Hilger, C. S.; Cook, G.; Warren, S.; Schmidt, P. G. Tumor targeting by an aptamer. J. Nucl. Med., 2006, 47, 668-678.
230. Lupold, S. E.; Hicke, B. J.; Lin, Y.; Coffey, D. S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res., 2002, 62, 4029-4033.
231. Bagalkot, V.; Farokhzad, O. C.; Langer, R.; Jon, S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl., 2006, 45, 8149-8152.
232. Dassie, J. P.; Liu, X. Y.; Thomas, G. S.; Whitaker, R. M.; Thiel, K. W.; Stockdale, K. R.; Meyerholz, D. K.; McCaffrey, A. P.; McNamara, J. O., 2nd; Giangrande, P. H. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA- expressing tumors. Nat. Biotechnol., 2009, 27, 839-849.
233. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103, 6315-6320.
234. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res., 2004, 64, 7668-7672.
235. Wang, A. Z.; Bagalkot, V.; Vasilliou, C. C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, M.; Yuet, K.; Cima, M. J.; Langer, R.; Kantoff, P. W.; Bander, N. H.; Jon, S.; Farokhzad, O. C. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem, 2008, 3, 1311-1315.
236. Zhang, L.; Radovic-Moreno, A. F.; Alexis, F.; Gu, F. X.; Basto, P. A.; Bagalkot, V.; Jon, S.; Langer, R. S.; Farokhzad, O. C. Codelivery of hydrophobic and hydrophilic drugs from nanoparticleaptamer bioconjugates. ChemMedChem, 2007, 2, 1268-1271.
237. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P. W.; Langer, R.; Farokhzad, O. C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano. Lett., 2007, 7, 3065-3070.